Get the app
US › Healthcare

Kala Pharmaceuticals Inc (KALA)

US · Healthcare · Biotechnology

$0.19-1.20%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-1.6M
EPS
$-21.32

Key statistics

Market cap
$5.7M
Forward P/E
0.0
P/B
1.20
Book value
$0.47
EPS (TTM)
$-10.71
52-week high
$95.50
52-week low
$0.29
50-day MA
$0.63
200-day MA
$9.11
Beta
-2.41

Analyst view

with an average price target of $1.50.

Shareholding

Insiders
1.24%
Institutions
4.07%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC1.14%
Geode Capital Management, LLC0.75%
Vanguard Fiduciary Trust Co0.52%
State Street Corp0.46%
BlackRock Inc0.37%
Northern Trust Corp0.22%
Qube Research & Technologies0.06%
The Goldman Sachs Group Inc0.06%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kala Pharmaceuticals Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.